SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Ocular Therapeutix Inc

Ocular Therapeutix is trending as the community eagerly anticipates topline Phase 3 SOL-1 data for its wet AMD treatment, AXPAXLI, set to be presented at a major scientific meeting, fueling discussions around potential positive results, a high-profile new CCO hire, and renewed acquisition interest following a prior rejected offer.

GSI Technology, Inc. engages in the design, development and marketing of memory products primarily for the networking, and telecommunications markets. Its product includes Static Random Access Memory, or SRAM, which incorporated in networking and telecommunications equipment, such as routers, switches, wide area network infrastructure equipment, wireless base stations and network access equipment. It also offers services to the ongoing needs of the military, industrial, test and measurement equipment, automotive and medical markets for SRAMs .The company was founded by Lee-Lean Shu and Robert Yau in March 1995 and is headquartered in Sunnyvale, CA.

GSI Technology Inc

GSI Technology is trending due to contrasting views on its Gemini-II AI chip's capabilities, with bulls highlighting recent preliminary benchmarks for low-power edge multimodal LLM inference and a government-backed defense project, while bears aggressively question the reported 3-second processing time and prior disclosures, prompting a law firm's securities investigation.

Nuvation Bio, Inc. is a biopharmaceutical company tackling some of the unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its proprietary portfolio includes six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. The company was founded by David Hung on March 20, 2018 and is headquartered in New York, NY.

Nuvation Bio Inc - Ordinary Shares - Class A

Nuvation Bio is trending amidst significant analyst upgrades and recent positive Phase 2 data for its safusidenib program, which demonstrates superior efficacy in glioma compared to competitors. Investors are optimistic about the robust commercial performance of IBTROZI, now with a 50-month duration of response and strong patient adoption, fueling discussions around the company's strategic focus, strong institutional buying, and substantial long-term growth potential under CEO David Hung's leadership.

Stafi is the first DeFi protocol unlocking liquidity of staked assets. Users can stake PoS tokens through Stafi and receive rTokens in return, which are available for trading while still earning staking rewards. FIS is the native token on Stafi Chain. FIS is required to provide security to the network by staking, pay for transaction fees on the Stafi chain, mint &amp; redeem rTokens.

StaFi

StaFi (FIS) is trending due to its recently announced token burn proposal aiming for deflationary tokenomics and a new roadmap, generating significant bullish sentiment within the community. Despite a recent delisting, many are anticipating substantial upside as a liquid staking protocol, citing its perceived low market cap and continued presence on major exchanges.

Bittensor is an open-source protocol that powers a decentralized, blockchain-based machine learning network. Machine learning models train collaboratively and are rewarded in TAO according to the informational value they offer the collective. TAO also grants external access, allowing users to extract information from the network while tuning its activities to their needs.  Ultimately, BitTensors vision is to create a pure market for artificial intelligence, an incentivized arena in which consumers and producers of this valuable commodity can interact in a trustless, open and transparent context.  Bittensor enables:  -A novel, optimized strategy for the development and distribution of artificial intelligence technology by leveraging the possibilities of a distributed ledger. Specifically, its facilitation of open access/ownership, decentralized governance, and the ability to harness globally-distributed resources of computing power and innovation within an incentivized framework.  -An open-source repository of machine intelligence, accessible to anyone, anywhere, thus creating the conditions for open and permission-less innovation on a global internet scale.  -Distribution of rewards and network ownership to users in direct proportion to the value they have added.

Bittensor

Bittensor (TAO CRYPTO) is generating significant buzz due to the recent Grayscale ETF filing and its imminent halving event, with the community actively discussing its potential as the "Bitcoin of AI" and the innovative utility offered by its decentralized subnet ecosystem.

Genius Sports Ltd. engages in the provision of scalable, technology-led products and services to the sports, sports betting, and sports media industries. It also involves in Sports League, which offers technology infrastructure for the collection, integration, and distribution of live data; Sportsbooks, which includes collection of live sports data, odds making, risk management and player marketing; and Sports Media, which provides a range of online marketing and fan engagement tools. The company was founded by Mark Adrian Locke in 2000 and is headquartered in London, United Kingdom.

Genius Sports Limited

Genius Sports is trending as its recent $1.2 billion acquisition of Legend, largely funded by debt and perceived by many as an overpay, has sparked widespread investor concern and selling pressure. While some see an overreaction and note management's insider buys as a sign of confidence, the community is actively debating the deal's strategic value amidst broader industry headwinds like the rise of prediction markets.

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals is trending as strong Dupixent sales and recent pipeline breakthroughs in oncology and gene therapy are battling ongoing manufacturing delays for its Eylea HD pre-filled syringe at a third-party facility, prompting community discussion on the stock's undervaluation despite short-term volatility.

Stem, Inc. engages in the provision of an energy storage system, hardware, ongoing software platform and professional services, and solar asset performance monitoring and control. The company was founded in 2009 and is headquartered in Houston, TX.

Stem Inc - Ordinary Shares - Class A

Stem Inc

Stem Inc. is trending due to speculative excitement surrounding its AI-enabled energy management software, following OpenAI and SoftBank's significant investment in its partner, SB Energy, for data center energy infrastructure. The community is actively discussing the company's potential to capitalize on surging AI-driven energy demand, while keenly anticipating upcoming earnings for validation amidst a history of volatility.

Lam Research Corp. engages in the design, manufacture, marketing, refurbishment, and provision of semiconductor processing equipment used in the fabrication of integrated circuits. It operates through the following geographical segments: United States, China, Europe, Japan, Korea, Southeast Asia and Taiwan. The company was founded by David K. Lam in 1980 and is headquartered in Fremont, CA.

Lam Research Corp.

Lam Research is a hot topic following its impressive earnings beat and strong guidance, driven by the insatiable demand for AI chips and aggressive fab expansions. The community is overwhelmingly bullish on its role in the semiconductor equipment sector, with many anticipating significant upside as analysts raise price targets.

MongoDB, Inc. engages in the development and provision of a general-purpose database platform. The firm's products include MongoDB Enterprise Advanced, MongoDB Atlas, and Community Server. It also offers professional services including consulting and training. The company was founded by Eliot Horowitz, Dwight A. Merriman, Kevin P. Ryan, and Geir Magnusson Jr. in November 2007 and is headquartered in New York, NY.

MongoDB Inc - Ordinary Shares - Class A

MongoDB Inc

MongoDB is trending after reporting a strong earnings beat and raised guidance, coupled with news of a new CEO and numerous analyst upgrades, igniting bullish sentiment around its Atlas cloud database and AI integrations. The community is actively debating MDB's high valuation versus its potential leadership in the evolving software and AI data infrastructure sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Positron Corp. operates as a nuclear medicine healthcare company, which engages in the provision of cardiac positron emission tomography imaging. It operates through the Medical Equipment and Radiopharmaceuticals segments. It offers economical, end-to-end solutions for Positron Emission Tomography (PET) myocardial perfusion imaging through complementary product integration of PET imaging systems, radiopharmaceuticals, and radioisotopes. The company was founded by Roman Oliynyk on December 20, 1983 and is headquartered in Niagara Falls, NY.

Positron Corp.

3%+ above current levels

Up 0–3%

Flat to down 3%

Down 3%+

The Nasdaq 100 continues to hinge on mega-cap tech and AI strength. With rate expectations shifting and valuations stretched, even a 3% move could signal a bigger trend. Is momentum building, or fading?

Current Price	$2.05
Prev Close	$1.97
Open	$2.24
Dividend Yield	0.00%
50-Day Moving Average	$1.66
Beta	0.22
Avg. Volume	6,017.30
PE Ratio	-16.58

52-Week High	$2.48
52-Week Low	$1.22
Market Capitalization	$28.12M
EPS (Annual)	-$0.0919
Price to Book	84.12
Revenue Per Employee	N/A

POSC
Positron Corp

Feed

News

Sentiment

Fundamentals

Info

Latest POSC News

POSCPositron Corp